Clinical trial NCT03994744: Assessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLC
Official title: A Phase II Open-label, Single-arm Study Assessing the Efficacy and Safety of Combination Therapy of Sintilimab and Metformin With Relapsed PD-L1 Positive Small Cell Lung Cancer
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Small-cell Lung Cancer
Small Cell Lung Carcinoma
Small Cell Lung Cancer Recurrent
Small Cell Lung Cancer Extensive Stage
Keywords: immunotherapy
metformin
PD-L1
PD-1 checkpoint inhibitor
Lead sponsor: Hunan Cancer Hospital
Sponsor class: OTHER
Collaborators: name: Xiangya Hospital of Central South University
name: Innovent Biologics (Suzhou) Co. Ltd.
First posted: 2019-06-21
Enrollment: 68
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Patients fulfilling Eligibility Criteria will be included in our study. Participants will be given intravenous administration of Sintilimab (1200mg/3w).

Metformin treatment will be given (day20) 1 week before the second administration of Sintilimab at a dose of 2000 mg daily (1000mg BID).

Treatments will be administrated for one year or until disease progression, death, or unacceptable toxicity.

Regular follow-up and safety assessment: Patients were assessed for drug safety and treatment efficacy every 2 cycles (6 weeks) in the first 3 months after enrollment, and then evaluated every 4 cycles (12 weeks). Assessment of tumor response, adverse events. Follow-up until disease progression and patient death.
Primary purpose: TREATMENT

Brief summary: In this Single arm study, histologically or cytologically confirmed ED-stage small cell lung cancer (SCLC) patients resistant to or relapsed after standard chemotherapy will be enrolled to investigate the Efficacy and Safety of a Combination of Sintilimab and Metformin.

Primary outcome:

Objective response rate (ORR), Safety of the combination therapy

Secondary outcome:

Overall survival (OS), Progression-free survival (PFS), Duration of response(DOR),

Detailed description: Exploratory Endpoints:

The association between the efficacy of the combination treatment and changes in CTC counts after administration of the treatment.

Evaluating the correlation between programmed death ligand 1 (PD-L1) expression derived from circulating tumor cells (CTC) and tumor tissue cells, and the predictive role of CTC PD-L1 expression in ED-SCLC.

The compositional changes in the gut microbiota after administration of the treatment and its association with the efficacy of the combination treatment.

Eligibility criteria: Inclusion Criteria:

1. Male or female patient, age≥18 and≤65;
2. Eastern Cooperative Oncology Group (ECOG) performance status ≤2;
3. The life expectancy of greater than 12 weeks;
4. Participants must have histologically or cytologically confirmed metastatic or extended disease of SCLC (ED-SCLC).
5. According to RECIST1.1, participants must have been confirmed Disease progression (within 6 months, confirmed by imaging test)after platinum-based doublet chemotherapy OR after (PFS\>6 months, ) platinum-based doublet chemotherapy and refused to continue chemotherapy, OR after second-line or more lines of systemic chemotherapy limited disease SCLC (LD-SCLC) patients with disease progression after Synchronous chemoradiotherapy, must receive firstline systematic platinum-based doublet chemotherapy and refused to receive chemotherapy again.
6. Evaluable or measurable lesion is required, defined as at least one lesion (not brain metastasis) that can be accurately measured based on RECIST 1.1;
7. Participant need to provided tumor tissue (from an archival tumor sample obtained within 1 year or from a new biopsy sample) for PD-L1 immunohistochemical (IHC) assay, and PD-L1expression in more than 1% cells is required;
8. Participant is able to the ability to swallow oral medications
9. Participants have to meet the following criteria to ensure function of vital organs:

   Absolute neutrophil count (ANC) ≥1.5×109/L or White blood cell count \>3.5×109/L;Platelets \>80×109/L; Hemoglobin (HGB)≥90 g/L;Serum total bilirubin ≤ 1.5 x upper limit of normal (ULN); AST(SGOT)/ALT(SGPT) ≤2.5 ×ULN; ALB≥2.8g/dL;Serum creatinine ≤ 1.5 x institutional ULN OR creatinine clearance ≥40 mL/min using the Cockcroft-Gault equation
10. Participants must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) through the treatment, and for at least 180 days after the last dose of study treatment; Participants must have the ability to understand and be willing to sign a written informed consent document.

Exclusion Criteria:

1. Participants who were diagnosed as mixed pathological type of small cell lung cancer
2. Participants who had long-term use of metformin (\>2 weeks) 6 months prior to study entry, or diagnosed with type-2 diabetes,
3. Participants received treatment with anti-PD1, -PDL1, -CTLA4, -CD137 inhibitors before, or any therapy specifically targeting T-cell co-stimulation or checkpoint pathways.
4. Participants received cellular immunotherapy before
5. Participants with Uncontrolled intercurrent illness including, but not limited to:

   Ongoing or active infection; Known history of Human Immunodeficiency Virus (HIV) infection Acute or chronic active hepatitis B (HBV DNA \>1\*10\^3 copies/ml or \>200 IU/mL) or, acute or chronic active hepatitis C (with a positive Hepatitis C antibody test result) Active tuberculosis Congestive heart failure (Class III-IV, according to New York Heart Association classification), or and clinically significant Cardiac arrhythmia if poorly controlled; Uncontrolled arterial hypertension (systolic blood pressure ≥160mmHg or diastolic blood pressure ≥100mmHg) Any arterial thrombosis, embolism, ischemia, myocardial infarction, unstable angina, or cerebrovascular accident within 6 months prior to enrollment,
6. Participants with symptomatic Central nervous metastasis or meningeal carcinomatosis are excluded; Participants with asymptomatic brain metastases or with brain metastases that have been treated and stable in a subsequent scan are allowed to include if there is measurable lesion outside the Central nervous system and no history of intracranial hemorrhage, and not midbrain, pons, cerebellum, medulla or spinal cord metastasis, and do not need glucocorticoid therapy.
7. Participants receiving glucocorticoid (\>30 mg prednisone equivalent a day) or any Immunosuppressive drug within 14 days prior to study recruitment; Participants receiving inhaled or Topical corticosteroids, adrenal corticosteroid replacement therapy (\>10 mg prednisone equivalent a day) are allowed if they have no active autoimmune disease
8. Participants with a known additional malignancy (Except for Non-melanoma skin cancer and the following in situ carcinoma: in situ bladder carcinoma, in situ gastric carcinoma, in situ colonic carcinoma, in situ endometrial carcinoma, in situ cervical carcinoma /dysplasia, in situ melanoma carcinoma and in situ breast Carcinoma) unless they Maintained Complete Remission for at least 5 years and do not need corresponding treatment during the study
9. Participants who have not recovered (i.e., ≤ Grade 1 according to NCI CTCAE V4or at baseline) from adverse effects due to a previously administered agent.
10. Participants who have uncontrollable effusion, such as pleural and ascites that cannot be controlled by drainage or other treatment
11. Patients who have active autoimmune diseases; excluding patients whose active autoimmune disease is caused by Vitiligo or asthma that is completely relieved in childhood and Patients with hypothyroidism requiring only hormone replacement therapy
12. Patients with known Allogeneic organ transplantation (except corneal transplantation) or allogeneic hematopoietic stem cell transplantation
13. Patients who are pregnant or breastfeeding,
14. Patients who are allergic to monoclonal antibody drugs
15. Patients who have contraindications to metformin including severe allergic reactions and intolerance
16. Patients who are not eligible for this study, as Assessed by Investigator

Primary outcomes:
measure: Objective response rate of Sintilimab and Metformin(ORR)
timeFrame: 1 year
measure: Safety of the combination therapy of Sintilimab and Metformin: CTCAE4.03 grading
timeFrame: 2 year
Secondary outcomes:
measure: Median overall survival (OS) time of Sintilimab and Metformin
timeFrame: 2 years
measure: Median progression free survival(PFS) of Sintilimab and Metformin
timeFrame: 1 year
measure: Median duration of response (DoR) of Sintilimab and Metformin
timeFrame: 1 year
Other outcomes:
Locations:
city: Changsha
country: China
facility: Hunan Cancer hospital
state: Hunan
Study officials:
affiliation: Hunan Cancer Hospital
name: Lin Wu
role: PRINCIPAL_INVESTIGATOR
References: